Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-023706
Filing Date
2025-09-04
Accepted
2025-09-04 17:00:24
Documents
1
Period of Report
2025-09-03

Document Format Files

Seq Description Document Type Size
1 form4-09042025_050913.html 4  
1 form4-09042025_050913.xml 4 6558
  Complete submission text file 0001415889-25-023706.txt   8296
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET, SCIENCE PARK CARMIEL Israel 2161401
Business Address
Melincoff Gwen A (Reporting) CIK: 0001614890 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 251294162